At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 1, Investigator-Blind, Subject-Blind, Sponsor-Open, Placebo-Controlled, Two-Week, Multiple Dose Escalation Study In Medically Stable Subjects With Psoriasis To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of CP-690,550
In Brief
A Phase 1 clinical trial evaluating tofacitinib for Psoriasis and Immunomodulation. Completed, enrolled 59 participants across 1 site.
Detailed Summary
This study was conducted in subjects with psoriasis to evaluate drug activity in this patient population by analysis of changes in psoriatic lesion biopsy characteristics. This subject population was selected to evaluate potentially relevant biological activity of CP-690,550 as well as assessing safety and pharmacokinetics.
Study Details
Timeline
Interventions
5 mg BID For 13 days and once on Day 14
10 mg BID for 13 days and once on Day 14\*
20 mg BID for 13 days and once on Day 14
30 mg BID for 13 days and once on Day 14
60 mg tablet once a day (QD) for 14 days
50 mg tablets two times a day (BID) for 13 days and once on day 14